Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H2 2019
Summary
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.
The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 5, 7, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Dermatology, Cardiovascular, Metabolic Disorders, Musculoskeletal Disorders and Undisclosed which include indications Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis (RRMS), Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Inflammatory Bowel Disease, Autoimmune Disorders, Inflammation, Psoriasis, Relapsing Multiple Sclerosis (RMS), Secondary Progressive Multiple Sclerosis (SPMS), Arthritis, Cerebral Aneurysms, Diabetic Retinopathy, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Neuroinflammation, Neuropathy, Osteoarthritis, Pain, Plaque Psoriasis (Psoriasis Vulgaris), Rett Syndrome, Sicca Syndrome (Sjogren), Stroke, Systemic Lupus Erythematosus and Unspecified.
Furthermore, this report also reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook